Imagine a world in which doctors can design a personalized treatment plan for you based on your particular genetic composition. Sounds futuristic, right? That future has arrived, owing to whole genome and exome sequencing.

The advent of organ-on-chip (OOC) technology has disrupted biomedical research, offering never-before-imagined opportunities to study human organ systems in vitro with remarkable accuracy.

The human microbiome is characterized by microbial communities that consist of beneficial bacteria, also known as microbiota. The microbiome creates a dynamic ecosystem inside the digestive system, contributing to the overall health of an individual.

The cell therapy technologies market size is expected to grow from $3.53 billion in 2022 to $4.24 billion in 2023 at a compound annual growth rate (CAGR) of 20%, according to The Business Research Company’s report Cell Therapy Technologies Global Market Report 2023.

The bio-manufacturing of recombinant proteins requires robust processes that can maximize protein yield from mammalian cell cultures while ensuring the efficacy of these proteins as human therapeutics.

Organ-on-chips (OOCs) are small plastic devices with biocompatible microfluid chambers containing multiple live human cells in a 3D culture that stimulate key physiological functions of body organs. The organ-on-chip market has grown 70.5% since 2015, reaching nearly $41.6 million in 2019, according to a report by The Business Research Company.

Genomic medicine has the potential to save lives, transform medical practice around the world, and drive billions of dollars of economic activity, according to a new white paper by BIS Research titled The Five Forces of Genomic Medicine.

According to Advances in Biopharmaceutical Technology in China, 2nd Ed, a report from BioPlan Associates, China is making strides in raising its Good Manufacturing Process (GMP) standards as it works to improve its global profile. GMP biopharmaceutical manufacturing has a short history in China, with the first version of guidance issued in 1998. In 2010, China's Ministry of Health released its fourth version of China GMP, with this iteration significantly raising the standards to be met by domestic biopharmaceutical developers.

Many have questioned whether China can move from "the world's factory” for consumer goods, electronics, and commodities, into technologically complex biologics.

It shouldn’t come as a surprise that biopharma in China is growing faster than many in the West have projected. A number of economic and development factors are contributing to this growth. But these have all been evolving for decades. 

So if there is a gap in Western (and in some cases China’s own internal) knowledge about this evolution, it should be put down to simply not paying enough attention.